| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/20/2002 | US20020076710 Detection and treatment of breast disease |
| 06/20/2002 | US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain |
| 06/20/2002 | US20020076702 Evaluating prostaglandin response to preferential modulators; obtain sample, incubate with modulator, compare profile with control, determine if human had prostaglandin response to moduator based on differences in control and sample profiles |
| 06/20/2002 | US20020076700 Nucleotide sequences coding secreted polypeptide; for use in treatment of cancer, autoimmune and skin disorders, allergies, infection, inflammation, arthritis, hematopoietic, atherosclerosis, restenosis and nervous system disorders |
| 06/20/2002 | US20020076693 Novel cell surface receptor for HIV retroviruses, therapeutic and diagnostic uses |
| 06/20/2002 | US20020076453 Angiotensin I-converting enzyme inhibitory substance |
| 06/20/2002 | US20020076447 Suspension or particle-solvent mixture system of zinc-containing calcium phosphate microparticle, and therapeutic agent for treating zinc deficiency |
| 06/20/2002 | US20020076441 A biodegradable gel matrix and a microparticle system wherein the microparticle is embedded in the biodegradable gel matrix, from which bioactive agent is released in a controlled manner |
| 06/20/2002 | US20020076420 For preventing the activation of these cells during an allergic response |
| 06/20/2002 | US20020076414 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 06/20/2002 | US20020076413 Administering fragments, conformations, biological equivalent, or derivatives of antithrombin III; anticancer agents |
| 06/20/2002 | US20020076412 Administering polypeptides derived from human myelin basic protein; for treatment of autoimmune diseases, multiple sclerosis |
| 06/20/2002 | US20020076409 Method for treating cancer |
| 06/20/2002 | US20020076407 Method for selectively stimulating proliferation of t cells |
| 06/20/2002 | US20020076406 Multivalent target binding protein |
| 06/20/2002 | US20020076404 Treating atopic dermatitis with IgE antagonists |
| 06/20/2002 | US20020076402 Glycolytic enzyme and its substrate and/or oligomers; chitinase, laminarinase and colloidal chitin into a film-forming preparation; protecting seeds, roots, bulbs |
| 06/20/2002 | US20020076401 Protection from stresses such as hypothermia, ischemia, oxidative stress, and hypoxia by inducing expression of heat shock proteins such as Hsp70 and Hsp27 on-demand in living cells |
| 06/20/2002 | US20020076399 Treatment of immune diseases |
| 06/20/2002 | US20020076398 Administering an agent that enhances Cyclic AMP response element binding protein (CREB) pathway function, training the animal to improve performance in the cognitive task; for people with central nervous system disorders |
| 06/20/2002 | US20020076395 Modified adipose tissue and related implants and methods |
| 06/20/2002 | DE10154224A1 Composition for treating cardiac insufficiency, containing a construct that expresses basic helix-loop-helix transcription factors |
| 06/20/2002 | DE10061525A1 New tetradecapeptides, containing alpha-aminoisobutyric acid residues and a terminal leucinol residue, useful for forming central nervous system-penetrating lipophilic conjugates of drugs, e.g. antibiotics |
| 06/20/2002 | CA2446832A1 Method of treating renal injury |
| 06/20/2002 | CA2439800A1 Isolated human kinase proteins, their encoding nucleic acid molecules, and uses thereof |
| 06/20/2002 | CA2436830A1 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 06/20/2002 | CA2434915A1 Therapeutic agent comprising a b-subunit of a protein toxin |
| 06/20/2002 | CA2431858A1 Targeted enzymes comprising substrate recognition sites and target binding sites |
| 06/20/2002 | CA2431800A1 Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| 06/20/2002 | CA2431716A1 Targeted enzyme prodrug therapy |
| 06/20/2002 | CA2431646A1 Non-invasive method for detecting target rna |
| 06/20/2002 | CA2431173A1 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 06/20/2002 | CA2430972A1 Fibrin fragments for treating inflammation |
| 06/20/2002 | CA2430906A1 Proteins associated with cell growth, differentiation, and death |
| 06/20/2002 | CA2430901A1 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 06/20/2002 | CA2430899A1 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test |
| 06/20/2002 | CA2430736A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/20/2002 | CA2430458A1 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| 06/20/2002 | CA2430454A1 Cddo-compounds and combination therapies thereof |
| 06/20/2002 | CA2430297A1 Interferon-alpha induced gene |
| 06/20/2002 | CA2428216A1 Secreted proteins |
| 06/20/2002 | CA2427271A1 Inflammatory markers for detection and prevention of diabetes mellitus |
| 06/20/2002 | CA2425513A1 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| 06/20/2002 | CA2365494A1 Lawsonia intracellularis vaccine |
| 06/20/2002 | CA2364984A1 Compositions comprising beta glucan and lactoferrin, and methods for their use |
| 06/19/2002 | EP1215497A1 Diagnostics for transmissible spongiform encephalopathy |
| 06/19/2002 | EP1215284A1 Tsg-like gene |
| 06/19/2002 | EP1215283A1 NOVEL bHLH TYPE TRANSCRIPTION FACTOR GENE DEC2 |
| 06/19/2002 | EP1215215A1 Platelet aggregation inhibitors containing c-terminal aminergic side chain amino acid residues |
| 06/19/2002 | EP1215214A1 Novel polypeptide |
| 06/19/2002 | EP1215213A2 Bicyclic amino-pyrazone derivatives, their preparation and pharmaceutical compositions containing them |
| 06/19/2002 | EP1215207A2 Salts of isoleucyl-thiazolidine and -pyrrolidine and their use as dipeptidylpeptidase inhibitors |
| 06/19/2002 | EP1214945A2 Method and medicament for inhibiting the expression of a defined gene |
| 06/19/2002 | EP1214943A1 T-cell therapeutics for transmissible spongiform encephalopathy and method for the manufacture of non-infective blood products and tissue derived products |
| 06/19/2002 | EP1214936A2 Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents |
| 06/19/2002 | EP1214933A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 06/19/2002 | EP1214601A2 Method for determining the fertility of mammals, especially of humans |
| 06/19/2002 | EP1214600A2 Determination of adrenomedullin-binding proteins |
| 06/19/2002 | EP1214598A2 Screening for inhibitors of "paired helical filaments" |
| 06/19/2002 | EP1214595A2 Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| 06/19/2002 | EP1214454A1 Hepatitis c virus replication inhibitors |
| 06/19/2002 | EP1214453A1 Novel cell cycle checkpoint genes and proteins encoded thereby |
| 06/19/2002 | EP1214452A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 06/19/2002 | EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 06/19/2002 | EP1214440A2 Sequence-specific dna recombination in eukaryotic cells |
| 06/19/2002 | EP1214429A1 Modulation of ige receptor cell surface expression |
| 06/19/2002 | EP1214428A1 Method for producing active serine proteases and inactive variants |
| 06/19/2002 | EP1214427A2 26176, a novel calpain protease and uses thereof |
| 06/19/2002 | EP1214426A2 Novel proteases and variants thereof |
| 06/19/2002 | EP1214423A1 Heparanase-2, a member of the heparanase protein family |
| 06/19/2002 | EP1214422A1 Phosphatases which activate map kinase pathways |
| 06/19/2002 | EP1214414A2 Rip-3-like death-associated kinase |
| 06/19/2002 | EP1214411A2 Flint analog compounds and formulations thereof |
| 06/19/2002 | EP1214409A1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 06/19/2002 | EP1214408A1 Ribozymes used for restenosis prevention |
| 06/19/2002 | EP1214401A2 Dna encoding the human serine protease c-e |
| 06/19/2002 | EP1214400A2 Zymogen activation system |
| 06/19/2002 | EP1214397A2 Method for the selective protection of proliferating normal cells and the selective eradication of tumor cells having an inactive p53 pathway |
| 06/19/2002 | EP1214396A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic |
| 06/19/2002 | EP1214351A2 Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| 06/19/2002 | EP1214350A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 06/19/2002 | EP1214349A2 Secreted soluble alpha2delta-2, alpha2delta-3 or alpha2delta-4 calcium channel subunit polypeptides and screening assays using same |
| 06/19/2002 | EP1214348A2 Parathyroid hormone analogues for the treatment of osteoporosis |
| 06/19/2002 | EP1214347A2 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 06/19/2002 | EP1214346A1 A novel angiogenesis inhibitor |
| 06/19/2002 | EP1214345A2 Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth |
| 06/19/2002 | EP1214344A1 Dipeptidyl peptidases |
| 06/19/2002 | EP1214342A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 06/19/2002 | EP1214340A2 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 06/19/2002 | EP1214337A2 Proteins associated with cell differentiation |
| 06/19/2002 | EP1214335A1 Gamma-carboxyglutamate containing conopeptides |
| 06/19/2002 | EP1214330A1 Benzimidazole derivatives and combinatorial libraries thereof |
| 06/19/2002 | EP1214092A2 Method of potentiating chemotherapy and treating solid tumors |
| 06/19/2002 | EP1214091A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 06/19/2002 | EP1214090A2 Novel uses of mammalian ccr6 receptors and related reagents |
| 06/19/2002 | EP1214089A1 Therapeutic uses of m3 polypeptide |
| 06/19/2002 | EP1214088A1 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 06/19/2002 | EP1214087A1 Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| 06/19/2002 | EP1214086A2 Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| 06/19/2002 | EP1214067A1 Methods for treating cell proliferative disorders including cancer |